Detalhe da pesquisa
1.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Blood;
139(8): 1160-1176, 2022 02 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35201323
2.
Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.
Bioorg Med Chem Lett;
24(6): 1506-10, 2014 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24560540
3.
Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first-in-human dose for acute myeloid leukemia.
Clin Transl Sci;
17(1): e13689, 2024 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37990450
4.
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Blood Adv;
8(9): 2059-2073, 2024 May 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38266153
5.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Nat Biotechnol;
41(9): 1296-1306, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36635380
6.
Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.
Bioorg Med Chem Lett;
22(20): 6381-4, 2012 Oct 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22981333
7.
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Oncoimmunology;
10(1): 1945803, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34484869
8.
Concomitant Inhibition of PI3Kß and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kß-Selective Inhibitor.
Mol Cancer Ther;
15(7): 1460-71, 2016 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27196754
9.
Discovery and optimization of pyrimidone indoline amide PI3Kß inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
J Med Chem;
57(3): 903-20, 2014 Feb 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24387221
10.
Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kß inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
J Med Chem;
55(10): 4788-805, 2012 May 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22524426